Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

27.83 -0.92 (-3.20%)
Streaming Delayed Price Updated: 1:04 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
News headline image
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗
This stock has been known to soar after good news. 
Via The Motley Fool
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
Could these two companies be biotech giants in the making? 
Via The Motley Fool
News headline image
Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗
The stock has climbed in the triple digits over the past three years. 
Via The Motley Fool
News headline image
3 Things Investors Need to Know About the Healthcare Sector in 2026 ↗
The most recent gold rush in weight loss drugs isn't done just yet. 
Via The Motley Fool
Topics Economy
VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report ↗
Via Stocktwits
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗
Via Stocktwits
News headline image
Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition
Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83... 
Via MarketMinute
Topics Earnings Economy
News headline image
The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts
In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a... 
Via MarketMinute
Topics Earnings Economy
News headline image
The Smartest Growth Stock to Buy With $30 Right Now ↗
This pre-revenue biopharmaceutical stock is a home run swing worth taking. 
Via The Motley Fool
News headline image
2 Biotech Stocks Set to Rebound in 2026 ↗
They could perhaps see sustained runs beyond this year. 
Via The Motley Fool
News headline image
Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? ↗
Both companies may succeed in this industry. 
Via The Motley Fool
News headline image
3 Growth Stocks to Invest $1,000 in Right Now ↗
It comes as no surprise that all three of them are capitalizing on relatively new, but game-changing, developments. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The Best Stocks to Invest $40 in to Start the New Year Off Right ↗
Both could reward patient investors down the line. 
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly
Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of... 
Via Finterra
Topics Intellectual Property
News headline image
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗
This biotech has candidates in late-stage clinical development. 
Via The Motley Fool
News headline image
The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era
Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally... 
Via MarketMinute
Topics Economy
News headline image
2 Bargain Stocks You Can Buy for Less Than $100 Right Now ↗
These stocks have struggled over the past year but may possess plenty of upside in the future. 
Via The Motley Fool
News headline image
1 Stock That Could Soar by 175%, According to Wall Street ↗
Can it become the next biotech leader? 
Via The Motley Fool
News headline image
What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? ↗
Despite a challenging year, the company has a lot to look forward to in the coming years. 
Via The Motley Fool
News headline image
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 ↗
Via MarketBeat
News headline image
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗
Via MarketBeat
Topics ETFs
News headline image
The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins
As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin... 
Via Finterra
Topics Economy
News headline image
The Great Rotation: Small-Caps Log Longest Winning Streak Against S&P 500 Since 2019
As of mid-January 2026, the U.S. equity markets are witnessing a historic recalibration that few analysts predicted eighteen months ago. The Russell 2000 index, the benchmark for American small-cap... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale ↗
This clinical-stage biotech developing metabolic therapies reported a notable insider sale amid a challenging year for its stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)
As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic... 
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era
As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands... 
Via MarketMinute
Topics Economy
News headline image
Small-Cap Slump: Russell 2000 Tumbles as Sticky Inflation Data Revives 'Higher-for-Longer' Fears
The Russell 2000 index, the primary benchmark for American small-cap stocks, suffered a significant sell-off on Wednesday, January 7, 2026, as a batch of conflicting economic data sparked fears that... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026
As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a... 
Via MarketMinute
Topics Economy
News headline image
The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall
As the first week of 2026 comes to a close, the financial markets are undergoing a significant structural shift. The broad-based "rising tide" that lifted almost all sectors throughout 2025 has begun... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.